These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 20032798

  • 1. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA, Komi JO, Ospemifene Study Group.
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [Abstract] [Full Text] [Related]

  • 2. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group.
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G.
    Menopause; 2019 Jan 28; 26(6):611-621. PubMed ID: 30694917
    [Abstract] [Full Text] [Related]

  • 5. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G, Graham S, Koltun WD, Kingsberg SA.
    J Sex Med; 2014 Apr 28; 11(4):1033-1041. PubMed ID: 24443923
    [Abstract] [Full Text] [Related]

  • 6. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J.
    Climacteric; 2016 Apr 28; 19(1):60-5. PubMed ID: 26669628
    [Abstract] [Full Text] [Related]

  • 7. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN, Clinard VB, Woodis CB.
    Pharmacotherapy; 2014 Oct 28; 34(10):1050-60. PubMed ID: 25052122
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J, Portman D, Mabey RG, Ospemifene Study Group.
    Maturitas; 2014 Mar 28; 77(3):274-81. PubMed ID: 24411556
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT, Kao CJ, DeGregorio MW.
    Clin Interv Aging; 2014 Mar 28; 9():1939-50. PubMed ID: 25419123
    [Abstract] [Full Text] [Related]

  • 10. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar 28; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 11. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA, Reape KZ, Wininger S, Hait H.
    Fertil Steril; 2008 Oct 28; 90(4):1132-8. PubMed ID: 18053998
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y, Zong H, Yan H, Li N, Zhang Y.
    J Sex Med; 2014 Feb 28; 11(2):487-97. PubMed ID: 24251418
    [Abstract] [Full Text] [Related]

  • 13. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.
    Menopause; 2010 Mar 28; 17(2):281-9. PubMed ID: 19779382
    [Abstract] [Full Text] [Related]

  • 14. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
    Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA.
    Climacteric; 2015 Apr 28; 18(2):233-40. PubMed ID: 25335119
    [Abstract] [Full Text] [Related]

  • 15. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
    Simon JA, Lin VH, Radovich C, Bachmann GA, Ospemifene Study Group.
    Menopause; 2013 Apr 28; 20(4):418-27. PubMed ID: 23096251
    [Abstract] [Full Text] [Related]

  • 16. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV.
    J Womens Health (Larchmt); 2018 Jan 28; 27(1):14-23. PubMed ID: 29064335
    [Abstract] [Full Text] [Related]

  • 17. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H.
    Menopause; 2009 Jan 28; 16(4):735-41. PubMed ID: 19252451
    [Abstract] [Full Text] [Related]

  • 18. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA, Schaefers M, Uddin A, Utian WH.
    Menopause; 2009 Jan 28; 16(5):877-82. PubMed ID: 19458560
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic evaluation of ospemifene.
    McCall JL, DeGregorio MW.
    Expert Opin Drug Metab Toxicol; 2010 Jun 28; 6(6):773-9. PubMed ID: 20429673
    [Abstract] [Full Text] [Related]

  • 20. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.
    Goldstein I, Simon JA, Kaunitz AM, Altomare C, Yoshida Y, Zhu J, Schaffer S, Soulban G.
    Menopause; 2019 Sep 28; 26(9):994-1001. PubMed ID: 31453961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.